Some joint changes need care sooner than others

Heat, heavy swelling, or fever calls for quick care

A joint that turns hot, very swollen, and painful may have an infection, especially if you feel ill, while swelling that grows quickly after any joint procedure also needs urgent care. A regular appointment isn’t soon enough for these warning signs. Urgent care can check the cause and begin the care you need.

You’ll want to take these changes seriously.

A fall or sudden weakness may need urgent help

After a fall, sudden trouble standing can mean a broken bone or other joint damage. You won’t want to wait if the joint locks, won’t move, or looks out of place. New loss of bowel or bladder control, numbness, or weakness may come from a nerve problem. Emergency care can check these changes without delay.

A regular, non-urgent visit can wait.

A regular exam begins with what hurts

For soreness that builds slowly, a doctor or licensed health professional will ask where it hurts and when it began. You can mention sleep, stairs, walking, dressing, or any movement that has become hard. During the exam, the health professional checks swelling and tender spots, joint movement, and strength. A scan may be ordered if the cause is still unclear.

What you’ve noticed helps guide the exam.

The visit should leave your choices clear

The health professional may discuss medicine, home care, physical therapy, surgery, or regenerative treatment made with material from a body. You’re welcome to ask which choice fits the exam and how much relief is realistic. Recovery time and warning signs that call for help also belong in the talk. The clinic shouldn’t assume one kind of care suits every sore joint.

You can leave knowing what comes next.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

4. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

6. The AAOS clinical practice guideline summary on SURGICAL management of knee osteoarthritis - the other end of the ladder, and the honest comparator for anyone told a biologic injection will let them avoid an operation.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee.. The Journal of the American Academy of Orthopaedic Surgeons, 2023. DOI: 10.5435/JAAOS-D-23-00338.